Truist Financial
JAZZ icon

Truist Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History

Truist Financial’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Sell
10,121
-86
-0.8% -$18.8K ﹤0.01% 1275
2026
Q1 		$1.93M Sell
10,207
-744
-7% -$130K ﹤0.01% 1350
2025
Q4 		$1.86M Sell
10,951
-21,747
-67% -$3.33M ﹤0.01% 1333
2025
Q3 		$4.31M Sell
32,698
-53
-0.2% -$6.36K 0.01% 957
2025
Q2 		$3.48M Buy
32,751
+148
+0.5% +$16.1K 0.01% 1025
2025
Q1 		$4.05M Buy
32,603
+4,054
+14% +$529K 0.01% 914
2024
Q4 		$3.52M Buy
28,549
+4,723
+20% +$557K 0.01% 980
2024
Q3 		$2.65M Sell
23,826
-10,496
-31% -$1.15M ﹤0.01% 1111
2024
Q2 		$3.66M Sell
34,322
-4,577
-12% -$503K 0.01% 998
2024
Q1 		$4.68M Sell
38,899
-507
-1% -$62.1K 0.01% 900
2023
Q4 		$4.85M Sell
39,406
-2,177
-5% -$272K 0.01% 873
2023
Q3 		$5.38M Buy
41,583
+11,168
+37% +$1.49M 0.01% 814
2023
Q2 		$3.77M Sell
30,415
-3,509
-10% -$472K 0.01% 955
2023
Q1 		$4.96M Sell
33,924
-2,336
-6% -$346K 0.01% 830
2022
Q4 		$5.78M Buy
36,260
+2,250
+7% +$330K 0.01% 771
2022
Q3 		$4.53M Buy
34,010
+4,908
+17% +$746K 0.01% 832
2022
Q2 		$4.54M Sell
29,102
-7,017
-19% -$1.08M 0.01% 839
2022
Q1 		$5.62M Sell
36,119
-14,596
-29% -$2.12M 0.01% 843
2021
Q4 		$6.46M Buy
50,715
+8,181
+19% +$1.08M 0.01% 795
2021
Q3 		$5.54M Buy
42,534
+3,657
+9% +$553K 0.01% 841
2021
Q2 		$6.91M Buy
38,877
+194
+0.5% +$33.6K 0.01% 759
2021
Q1 		$6.36M Sell
38,683
-5,907
-13% -$972K 0.01% 756
2020
Q4 		$7.36M Buy
44,590
+5,486
+14% +$817K 0.01% 690
2020
Q3 		$5.58M Buy
39,104
+1,418
+4% +$176K 0.01% 723
2020
Q2 		$4.16M Buy
37,686
+5,688
+18% +$629K 0.01% 767
2020
Q1 		$3.19M Sell
31,998
-20,688
-39% -$2.67M 0.01% 801
2019
Q4 		$7.87M Buy
+52,686
New +$7.17M 0.02% 631
2014
Q3 		– Sell
-1,377
Closed -$202K – 777
2014
Q2 		$202K Buy
+1,377
New +$191K 0.01% 759

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Truist Financial's JAZZ Position: Q2 2026 in Review

Truist Financial reduced its Jazz Pharmaceuticals (JAZZ) stake by 0.84% in Q2 2026, selling an estimated $18.8K and leaving 10,121 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1275.

Truist Financial first reported a position in JAZZ in Q2 2014 and has held it in 28 quarters since. The position peaked at $7.87M in Q4 2019. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Truist Financial held 10,121 shares of Jazz Pharmaceuticals worth $2.44M as of Q2 2026.
  • Truist Financial sold 86 Jazz Pharmaceuticals shares in Q2 2026, an estimated $18.8K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1275 holding.
  • Truist Financial first reported a position in Jazz Pharmaceuticals in Q2 2014 and has held it in 28 quarters since.
  • Truist Financial's Jazz Pharmaceuticals position peaked at $7.87M in Q4 2019.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.